Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia.

ABSTRACT:

Background

Mitoxantrone hydrochloride liposome (Lipo-MIT) exhibits encouraging efficacy in treating multiple hematologic malignancies. This study evaluated the real-world efficacy and safety of Lipo-MIT-containing regimens in the treatment of acute myeloid leukemia (AML).

Methods

This noninterventional, ambispective cohort study was conducted at 42 centers in China. Patients with newly diagnosed or relapsed/refractory AML who received Lipo-MIT-containing regimens were included. The primary endpoint was the composite complete remission (CRc) rate.

Results

Between January 2022 and December 2023, 117 patients with newly diagnosed AML and 122 patients with relapsed/refractory AML were included. The CRc and objective response rates were 84.6% (95% confidence interval [CI],

SUBMITTER: Gong TJ 

PROVIDER: S-EPMC12558270 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature